26 September 2024 - BEAM AllianceNew York, From inside the UN buildings – Remko van LeeuwenJust a few hours ago the General Assembly of the UN has adopted a new declaration on fighting AMR. Regardless…read more >>
17 September 2024 - BEAM AllianceBEAM’s Reflection paper on General Pharmaceutical Legislation Revision: Taking Stock of the EU Parliament Position and Moving ForwardThe BEAM Alliance would like to reiterate its call for optimal PULL incentives designed to fit innovators’ needs based on…read more >>
24 October 2023 - BEAM AllianceBEAM Alliance shares its views on the ongoing revision of the General Pharmaceutical LegislationWe call on policymakers to stop postponing decisions and either propose a clear incentive package now or reintroduce the TEE…read more >>
05 September 2023 - BEAM AllianceBEAM Alliance is Launching a new Task Force to address Issues from the AMR Diagnostics SegmentThe new Task Force is gathering innovative SMEs operating in the AMR field and external experts.read more >>
16 June 2023 - BEAM AllianceBEAM’s reflection paper on the possible roles of DG HERAThe report represents an important step towards the implementation of a tangible solution to fix the AMR market. Although the…read more >>
23 May 2023 - BEAM AllianceBEAM’s statement on the EU Council Recommendation on AMRThe proposal examines AMR in a rather exhaustive way. It includes provisions on the need to strengthen national action plans,…read more >>
15 December 2023 - AdjuTec Pharma ASAdjuTec Pharma is Awarded NOK 16mill to Support Clinical TrialsThis award is fantastic news that will secure fast-track development of our lead product APC148. APC148 combined with antibiotics, restores…read more >>
12 December 2023 - ANTABIO S.A.SANTABIO Raises €25 million in Series B FinancingWe are thrilled to welcome the AMR Action Fund and the EIC Fund to Antabio, and grateful to our historical…read more >>
12 December 2023 - BioVersys AGBioVersys receives U.S. FDA orphan-drug designation for alpibectir and ethionamide fixed-dose combination for treatment of tuberculosisThis U.S. FDA ODD is a great qualification of our development approach to deliver urgently needed therapeutic solutions for the…read more >>
11 December 2023 - BasileaBasilea announces that FDA approves expanded use of antifungal Cresemba® (isavuconazole) in the United States in children with invasive aspergillosis and invasive mucormycosisDr. Marc Engelhardt, Chief Medical Officer of Basilea, said: “We congratulate Astellas on the approval of Cresemba for the use…read more >>
05 December 2023 - Eligo BioscienceEligo Bioscience Raises $30 Million To Write a Novel Chapter for Genetic MedicinesEligo stands at the forefront of a biotechnological revolution. By focusing on the in-vivo delivery of genetic cargoes to the…read more >>
13 November 2023 - BasileaBasilea announces acquisition of fosmanogepix, a phase-3-ready broad-spectrum antifungalFosmanogepix is a potential first-in-class antifungal treatment candidate with a novel mechanism of action. It is available in intravenous and…read more >>
17 March 2025BIO-Europe Spring® 2025 – 19th Annual International Partnering ConferenceBIO-Europe Spring will bring together over 3,700 leading executives from around the world. Specifically, we will host more than 20,000…read more >>
25 February 20259th AMR ConferenceSave the date! The 9th AMR Conference will be organized as a face-to-face event on 25-26 February 2025, in Basel.…read more >>
03 December 2024REVIVE Webinar: Implementation research for the appropriate use of, and access to, antimicrobialsThis webinar will explore how implementation research has successfully led to the updating of guidelines for other drugs and discuss…read more >>
04 November 2024BIO-Europe ® 2024 – 30th Annual International Partnering ConferenceOver the last 30 years, BIO-Europe, has become Europe’s flagship partnering event. Its international reach makes it a one-of-a-kind offering,…read more >>
19 September 2024REVIVE Webinar: An introduction to antibiotic research and development (R&D)Itroduction to the stages from discovery to the phases of clinical trials and pharmaceutical development - A must-watch for clinicians…read more >>
22 August 2024REVIVE Webinar: Exploring non-traditional antimicrobials: Insights from three casesFind out the latest in the development of non-traditional antimicrobials from Jennifer Schneider at Centauri Therapeutics, Rida Mourtada at Lytica…read more >>
23 July 2024REVIVE Webinar: The value of surveillance data in defining the medical need for new antimicrobialsIn this webinar, the speakers will show the value of susceptibility surveillance data in defining the need for new antibacterials,…read more >>
27 June 2024REVIVE Webinar: Progressing an antibacterial drug discovery project – an SME perspectiveAlisa Serio from Paratek Pharma and Victoria Savage from INFEX Therapeutics will focus on the particular challenges, progression criteria and…read more >>
23 April 2024REVIVE Webinar: Efflux inhibitors: A strategy to tackle multidrug resistanceThe next REVIVE webinar will feature an overview of bacterial efflux and how molecules designed to inhibit this can be…read more >>
